Avanafil Impotence Drug Clinical Data Looking Good
Written by Jamie Stowe| Friday, 20 January 2012| There is 1 comment
More data surrounding clinical trials of the new erectile dysfunction medication avanafil being researched by Vivus Inc shows that the drug has a significant positive impact on erectile function. The study which looked at the effectiveness and the safety of 50mg, 100mg and 200mg avanafil doses was recently evaluated in The Journal of Sexual Medicine.
The results of the study called REVIVE (TA-301) showed that around 2/3 men suffering from erectile dysfunction who took avanafil were able to have sexual intercourse with in fifteen minutes of taking the drug. It was observed that those men who took 50mg of avanafil had a 64 percent success rate, those who took 100mg had a 67 percent success rate and those who took 200mg of avanafil had a 71 percent success rate. Only 27 percent of the men who were given a placebo tablet were able to have sexual intercourse within fifteen minutes.
The manufacturer of avanafil is positioning the drug to be different from Viagra, Cialis and Levitra in that it works much faster than its rivals. The idea is that men who want to have spontaneous sexual activity and do not want to wait around for the drug to kick in might choose avanafil for its quick application.
Avanafil has been reviewed by numerous American Food & Drug Administration monitored studies and it is hoped that a decision about whether the drug will be given full approval for sale and marketing will be forthcoming by the end of April, 2012. Vivus will be submitting data to the EMEA for possible sale and marketing approval in the European Union sometime this year.
At Ukmedix News we are reasonably confident that avanafil will receive full approval because it belongs to the same family of drugs, namely PDE5 inhibitors which Viagra, Cialis and Levitra belong to. Ukmedix News will keep you updated with any developments on this new erectile dysfunction medication.